As part of their standard care, all patients underwent a core needle biopsy prior to treatment to confirm the cancer diagnosis; determine the histological subtype; and assess hormone receptor status, including estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor (HER2) in order to classify the tumor’s molecular subtype. The gene discussed is NR4A1; the disease is neoplasm.